ANEW Medical (NASDAQ:WENA) has been granted and issued a patent from the European Patent Office (EPO) for the patent application covering the company’s secreted Klotho gene sequence and gene delivery system, intended for the treatment of diminished cognition, memory loss, dementia, and other neurodegenerative diseases.
Licenced on an exclusive worldwide basis from Universitat Autònoma de Barcelona and Institució Catalina de Recerca i Estudis Avançats, in Barcelona, Spain, the company has patent approval in China and Hong Kong and plans to expand its IP portfolio into the Asian markets this year.
In a statement, Dr. Joseph Sinkule, founder and CEO of ANEW, said, “These assets play a vital role in our international product development efforts for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and ALS. We believe our secreted Klotho RNA splice variant programs for cell and gene therapy, along with the related protein and genomics diagnostic programs, represent a groundbreaking approach to identifying and treating these devastating diseases.”
